The American Society of Gene and Cell Therapy (ASGCT) is recommending that the National Institutes of Health’s Recombinant DNA Advisory Committee (RAC) should terminate review of individual gene therapy clinical protocols and instead identify “new areas of research” that require a public forum for discussion and review.
The non-profit ASGCT represents the interests of gene and cell therapy researchers by liaising with the NIH and other governmental agencies.
This article is only available to Research Professional News subscribers or Pivot-RP users.
If you are a Research Professional News subscriber you can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.